Novel vaccine could counter dangerous effects of synthetic cannabinoids
Posted: 28 December 2020 | Victoria Rees (Drug Target Review) | No comments yet
In pre-clinical trials, researchers have shown that a new vaccine could combat the dangerous effects of synthetic cannabinoids.


In a new study, scientists have devised a way to deactivate dangerous synthetic cannabinoids after they have been administered – offering a potential path for treating addiction and overdose. The study was conducted at Scripps Research, US.
According to the researchers, synthetic cannabinoids act on the same brain cell receptors as tetrahydrocannabinol (THC). However, they are made in a laboratory, with chemical structures that do not look like THC. Moreover, their actual effects can be unpredictable and in some cases, fatal.
The team developed a vaccine that was able to broadly counter the effects of synthetic cannabinoids in rodents, sequestering the drug molecules before they could interact with the central nervous system (CNS).
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
The new vaccine is composed of multiple drug-like antigens that stimulate broadly neutralising antibodies within the body, which disable many types of cannabinoids. The team say that this is key, as synthetic cannabinoids encompass a wide range of man-made chemicals.
In behavioural experiments involving mice, the team found that even when exposed to a large amount of the drug, the vaccine offered broad protection against the psychoactive effects. The team also developed a version of the vaccine that could be inhaled, which could offer greater convenience.
“Synthetic cannabinoids are much more powerful and toxic than users often realise and their rising prevalence has led to serious health issues among young people and adults,” lead researcher Dr Kim Janda said. “We found a way to negate the dangerous effects of these drugs, even when they are consumed in impure forms, as is often the case. Our hope is that this may one day help treat cannabinoid use disorders or accelerate recovery for people who overdosed.”
The study appears in the American Chemical Society’s journal JACS Au.
Related topics
Cannabinoids, Drug Development, Research & Development, Vaccine
Related conditions
Addiction
Related people
Dr Kim Janda


